Toronto Dominion Bank Takes Position in Omnicell, Inc. (NASDAQ:OMCL)

Toronto Dominion Bank bought a new position in shares of Omnicell, Inc. (NASDAQ:OMCL) during the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund bought 688,161 shares of the company’s stock, valued at approximately $30,637,000.

A number of other institutional investors have also made changes to their positions in OMCL. Smartleaf Asset Management LLC raised its holdings in Omnicell by 51.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after acquiring an additional 273 shares during the period. Summit Investment Advisors Inc. boosted its holdings in shares of Omnicell by 6.9% during the fourth quarter. Summit Investment Advisors Inc. now owns 4,774 shares of the company’s stock worth $213,000 after acquiring an additional 307 shares during the period. Van ECK Associates Corp grew its position in shares of Omnicell by 47.0% in the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock valued at $44,000 after purchasing an additional 315 shares during the last quarter. First Horizon Advisors Inc. increased its stake in shares of Omnicell by 36.3% during the fourth quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after purchasing an additional 355 shares during the period. Finally, Redmond Asset Management LLC increased its stake in shares of Omnicell by 0.3% during the fourth quarter. Redmond Asset Management LLC now owns 121,209 shares of the company’s stock worth $5,396,000 after purchasing an additional 371 shares during the period. 97.70% of the stock is owned by institutional investors and hedge funds.

Analysts Set New Price Targets

Several analysts recently issued reports on OMCL shares. Wells Fargo & Company upgraded Omnicell from an “equal weight” rating to an “overweight” rating and boosted their price target for the company from $31.00 to $35.00 in a research note on Wednesday, May 14th. StockNews.com cut shares of Omnicell from a “buy” rating to a “hold” rating in a research report on Saturday, May 3rd. JPMorgan Chase & Co. decreased their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating on the stock in a research note on Thursday, March 20th. Finally, Benchmark dropped their price objective on shares of Omnicell from $62.00 to $40.00 and set a “buy” rating for the company in a research note on Wednesday, May 7th. Four analysts have rated the stock with a hold rating and three have issued a buy rating to the stock. According to MarketBeat.com, the stock has an average rating of “Hold” and a consensus target price of $46.50.

Omnicell Stock Performance

NASDAQ:OMCL opened at $27.96 on Monday. The company has a market cap of $1.31 billion, a price-to-earnings ratio of 103.56, a PEG ratio of 7.53 and a beta of 0.78. Omnicell, Inc. has a fifty-two week low of $22.66 and a fifty-two week high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The stock has a fifty day moving average price of $31.41 and a 200-day moving average price of $39.40.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings results on Tuesday, May 6th. The company reported $0.26 EPS for the quarter, beating analysts’ consensus estimates of $0.16 by $0.10. The business had revenue of $269.67 million during the quarter, compared to the consensus estimate of $260.18 million. Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Omnicell’s revenue for the quarter was up 9.5% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.03 earnings per share. As a group, equities analysts anticipate that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.